Compare FCAP & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCAP | SCLX |
|---|---|---|
| Founded | 1891 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.9M | 139.3M |
| IPO Year | 1999 | N/A |
| Metric | FCAP | SCLX |
|---|---|---|
| Price | $48.15 | $19.93 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.0K | ★ 122.8K |
| Earning Date | 01-23-2026 | 11-14-2025 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 25.19 | N/A |
| EPS | ★ 4.41 | N/A |
| Revenue | ★ $47,323,000.00 | $40,360,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $749.70 |
| P/E Ratio | $11.52 | ★ N/A |
| Revenue Growth | ★ 15.22 | N/A |
| 52 Week Low | $28.50 | $3.60 |
| 52 Week High | $53.85 | $34.27 |
| Indicator | FCAP | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 69.75 | 51.13 |
| Support Level | $47.48 | $18.34 |
| Resistance Level | $50.95 | $20.62 |
| Average True Range (ATR) | 0.99 | 2.22 |
| MACD | 0.37 | -0.02 |
| Stochastic Oscillator | 97.55 | 32.91 |
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.